Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Phuong T. Vo, MD, Ted Gooley, PhD, Joseph G. Rajendran, MD, Darrell R. Fisher, PhD, Johnnie J. Orozco, MD PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Robyn Haaf, BS, Margaret E. Nartea, BS, Rainer F. Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD PhD, John M. Pagel, MD PhD, Brenda M. Sandmaier, MD

Blood (2018) 132 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2018-99-111915

Published: 2018

Journal Articles

Prognostic Value of Single-Photon Emission Computed Tomography of Left Ventricular Synchronized with ECG for Cardiotoxicity Assessment in Patients with Malignant Lymphoma after High Dose Chemotherapy with Autologous Stem Cell Transplantation

Dina Kolesnikova, MD

Blood (2017) 130 (Supplement 1): 5501.

https://doi.org/10.1182/blood.V130.Suppl_1.5501.5501

Published: 2017

Journal Articles

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Blood (2017) 130 (Supplement 1): 2048.

https://doi.org/10.1182/blood.V130.Suppl_1.2048.2048

Published: 2017

Journal Articles

A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Jostein Dahle, PhD, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Bjørg Bolstad, MSc, Nils Bolstad, MD, Anne Tierens, MD PhD, Roy Hartvig Larsen, PhD, Jan Alan Alfheim, MSC, MBA, Jan Delabie, MD PhD, Spetalen Signe, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, MD PhD

Blood (2014) 124 (21): 3094.

https://doi.org/10.1182/blood.V124.21.3094.3094

Published: 2014

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Rebecca L. Elstrom, MD, John P. Leonard, MD, Paul Christos, Peter Martin, MD, Daniel Lebovic, MD, Joseph Osborne, Stanley J. Goldsmith, June Greenberg, RN, Richard R. Furman, MD, Jia Ruan, MD, PhD, Ryan Putman, Erica Chapman, Madhu Mazumdar, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2012) 120 (21): 1636.

https://doi.org/10.1182/blood.V120.21.1636.1636

Published: 2012

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,

Rebecca Elstrom, MD, John P. Leonard, MD, Stanley J. Goldsmith, Paul Christos, Peter Martin, Joseph Osborne, Daniel Lebovic, MD, Ramsey Abdallah, CRC, June Greenberg, Richard R. Furman, MD, Jia Ruan, MD, PhD, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2011) 118 (21): 3712.

https://doi.org/10.1182/blood.V118.21.3712.3712

Published: 2011

Journal Articles

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

Thierry J. Horner, PhD, Jeffry A. Siegel, MS, MS, PhD, Roxanne C. Jewell, PhD, Gary J. Lunger, MSRIS, RT(R)(N)ARRT, Nancy L. Young, BS, NMT, Brian R. Wynne, MD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Mark S. Kaminski, MD, Richard L. Wahl, MD, Christina Vleisides, DC

Blood (2010) 116 (21): 4916.

https://doi.org/10.1182/blood.V116.21.4916.4916

Published: 2010

Journal Articles

Autologous 111 In-Labeled Platelet Sequestration Studies in Patients with Primary Immune Thrombocytopenia (ITP): A Report From the United Kingdom Registry.

Ameet Sarpatwari, M.Phil, Drew Provan, MD, Ravin Sobnack, PhD, Sebhat Erqou, MD, M.Phil, F. W. David Tai, BSc., Simon Sanderson, MD, Adrian Newland, MD, FRCP

Blood (2009) 114 (22): 2406.

https://doi.org/10.1182/blood.V114.22.2406.2406

Published: 2009

Journal Articles

Effect of Prior Rituximab on Residence Time of I131 Tositumomab Consolidation Therapy in Patients (pts) with Non Hodgkin’s Lymphoma (NHL): Analysis of SWOG Clinical Trials.

Julia Schaefer-Cutillo, Vaseem Chengazi, Derick R Peterson, David G. Maloney, Kevin Kibler, Erin Cebula, Steven Bernstein, Faith Young, Oliver W. Press, Lisa M. Rimsza, Richard I. Fisher, Jonathan W. Friedberg, MD

Blood (2008) 112 (11): 2000.

https://doi.org/10.1182/blood.V112.11.2000.2000

Published: 2008

Journal Articles

An Animal Model to Study Bisphosphonates Associated Osteonecrosis of the Jaw

Gabriele Pozzato, MD, Silvia Chiandussi, Sr., Serena Zacchigna, Franca Dore, Silvia Moimas, Fabrizio Zanconati, Fabio Cavalli, Arturo Mecchia, Michela Faraon, Mauro Giacca, Roberto Di Lenarda, Mauro Giacca, Matteo Biasotto

Blood (2008) 112 (11): 3659.

https://doi.org/10.1182/blood.V112.11.3659.3659

Published: 2008

Journal Articles

Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

Thomas P. Miller, MD, Joseph M Unger, MS, Catherine Spier, MD, Baldassarre Stea, MD, PhD, Oliver W. Press, MD, PhD, Jonathan W. Friedberg, MD, Michael LeBlanc, PhD, Richard I Fisher, MD

Blood (2008) 112 (11): 3598.

https://doi.org/10.1182/blood.V112.11.3598.3598

Published: 2008

Journal Articles

A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).

Thomas E. Witzig, MD, Gregory A. Wiseman, MD, George Weiner, MD, Stephen M. Ansell, MD, PHD, Ivana Micallef, MD, Thomas M. Habermann, MD, Clive S. Zent, MD, David J. Inwards, MD, Tait Shanafelt, MD, Luis Porrata, MD, Matthew J. Maurer, MS, Cristine Allmer, Zuhair Ballas, MD

Blood (2007) 110 (11): 124.

https://doi.org/10.1182/blood.V110.11.124.124

Published: 2007

Journal Articles

Phase I Evaluation of Immune Therapy with Ex-Vivo Expanded and Activated Gamma Delta T Cells.

Qiao Wang, Jacqueline S. Morley, Hang-Fai So, Stephen R. Mattarollo, Tomomi Hagi, Hirotake Tokuyama, Vy Truong, Mie Nieda, Kiyoshi Yokokawa, Andrew Nicol

Blood (2006) 108 (11): 5196.

https://doi.org/10.1182/blood.V108.11.5196.5196

Published: 2006

Journal Articles

In-111DAC Is a Novel Technique To Image Multiple Myeloma.

Patricia T. Greipp, DO, Douglas A. Collins, MD, Stephen J. Russell, MD, PhD, Mary E. Harvey, Apollina Goel, PhD, Philip R. Greipp, MD

Blood (2006) 108 (11): 3488.

https://doi.org/10.1182/blood.V108.11.3488.3488

Published: 2006

Journal Articles

A Pilot Study of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Relapsed and Refractory Classical Hodgkin Lymphoma (HL): Delivering Cross Fire Radiation by Targeting Reactive B Cells in the Microenvironment.

Anas Younes, MD, Jorge E. Romaguera, MD, Peter McLaughlin, MD, Franklin Wong, MD, PhD

Blood (2005) 106 (11): 4791.

https://doi.org/10.1182/blood.V106.11.4791.4791

Published: 2005

Journal Articles

Tracking Dendritic Cells In Vivo in Patients with Multiple Myeloma.

Dominic M. Wall, PhD, Mick Thompson, BSc, Linda Mileshkin, MBBS, FRACP, Bruce Loveland, PhD, Judi Coverdale, BSc, Pei-Xiang Xing, PhD, Jacques Bartholeyns, PhD, Rodney Hicksm, MBBS, MD, FRACP, Miles Prince, MBBS, MD, FRACP, FRCPA

Blood (2005) 106 (11): 3469.

https://doi.org/10.1182/blood.V106.11.3469.3469

Published: 2005

Journal Articles

CD30 as Target for Radioimmunotherapy (RIT) of Lymphoma.

Jan O. Staak, MD, David Colcher, PhD, Satoshi Nagata, PhD, Jianyi Wang, Ira H. Pastan, MD, Andrew A. Raubitschek, MD

Blood (2005) 106 (11): 1501.

https://doi.org/10.1182/blood.V106.11.1501.1501

Published: 2005

Journal Articles

TECHNITIUM-99m-SESTAMIBI SCANNING (MIBI) CORRELATES WITH DISEASE ACTIVITY IN PATIENTS (PTS) WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT).

Natalie S. Callander, MD, William T. Phillips, MD, Darlene F. Metter, MD, Leonel Ochoa-Bayona, MD, Cesar O. Freytes, MD, Sharon A. Primeaux, MS

Blood (2004) 104 (11): 2469.

https://doi.org/10.1182/blood.V104.11.2469.2469

Published: 2004

Journal Articles

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

David Dingli, Kah-Whye Peng, Mary E. Harvey, Philip R. Greipp, Michael K. O'Connor, Roberto Cattaneo, John C. Morris, Stephen J. Russell

Blood (2004) 103 (5): 1641–1646.

https://doi.org/10.1182/blood-2003-07-2233

Published: 2004

NARROW

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Prognostic Value of Single-Photon Emission Computed Tomography of Left Ventricular Synchronized with ECG for Cardiotoxicity Assessment in Patients with Malignant Lymphoma after High Dose Chemotherapy with Autologous Stem Cell Transplantation

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

Autologous 111 In-Labeled Platelet Sequestration Studies in Patients with Primary Immune Thrombocytopenia (ITP): A Report From the United Kingdom Registry.

Effect of Prior Rituximab on Residence Time of I131 Tositumomab Consolidation Therapy in Patients (pts) with Non Hodgkin’s Lymphoma (NHL): Analysis of SWOG Clinical Trials.

An Animal Model to Study Bisphosphonates Associated Osteonecrosis of the Jaw

Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).

Phase I Evaluation of Immune Therapy with Ex-Vivo Expanded and Activated Gamma Delta T Cells.

In-111DAC Is a Novel Technique To Image Multiple Myeloma.

A Pilot Study of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Relapsed and Refractory Classical Hodgkin Lymphoma (HL): Delivering Cross Fire Radiation by Targeting Reactive B Cells in the Microenvironment.

Tracking Dendritic Cells In Vivo in Patients with Multiple Myeloma.

CD30 as Target for Radioimmunotherapy (RIT) of Lymphoma.

TECHNITIUM-99m-SESTAMIBI SCANNING (MIBI) CORRELATES WITH DISEASE ACTIVITY IN PATIENTS (PTS) WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT).

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only